Castle Biosciences expects preliminary full‑year 2025 revenue of $340 million, above prior guidance and consensus, driven by a 37% year‑over‑year increase in test reports. The company delivered notable growth in DecisionDx‑Melanoma and TissueCypher Barrett's Esophagus reports and highlighted rising volumes across its oncology and prognostic testing portfolio. Castle reported solid cash and marketable securities positions heading into 2026.